Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Richardson, Debra L.
Barve, Minal A.
Strauss, James Fredric
Ulahannan, Susanna Varkey
Moore, Kathleen N.
Hamilton, Erika Paige
Johnson, Melissa Lynne
Papadopoulos, Kyriakos P.
Zarwan, Corrine
Anderson, Charles K.
Buscema, Joseph
Doroshow, Deborah Blythe
Edenfield, William Jeffery
Matulonis, Ursula A.
Burns, Timothy F.
Huebner, Dirk
Jansen, Valerie Malyvanh
Mosher, Rebecca
Jarlenski, Donna
Tolcher, Anthony W.
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Sarah Cannon Res Inst, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Mary Crowley Canc Res Ctr, Dallas, TX USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[5] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[6] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[7] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[8] Lahey Hosp & Med Ctr, Burlington, MA USA
[9] Willamette Valley Canc Inst, Eugene, OR USA
[10] Arizona Oncol Associates, Tucson, AZ USA
[11] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA
[12] Prisma Hlth Upstate Canc Inst, Inst Translat Oncol Res, Greenville, SC USA
[13] Dana Farber Canc Inst, Boston, MA 02115 USA
[14] Univ Pittsburgh, Med Ctr UPMC, Hillman Canc Ctr, Pittsburgh, PA USA
[15] Mersana Therapeut Inc, Cambridge, MA USA
[16] NEXT Oncol, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3549
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer
    Lu, Shun
    Zhou, Qing
    Liu, Xiaoqing
    Du, Yingying
    Fan, Yun
    Cheng, Ying
    He, Shan
    Zhao, Huadong
    Li, Heyan
    Wu, Yi-Long
    CLINICAL LUNG CANCER, 2024, 25 (07)
  • [42] Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).
    Camidge, D. Ross
    Heist, Rebecca Suk
    Masters, Gregory A.
    Scheff, Ronald J.
    Starodub, Alexander
    Messersmith, Wells A.
    Bardia, Aditya
    Ocean, Allyson J.
    Horn, Leora
    Berlin, Jordan
    Maliakal, Pius P.
    Sharkey, Robert M.
    Wilhelm, Francois
    Goldenberg, David M.
    Guarino, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: preliminary results
    Ross, HJ
    Blumenschein, GR
    Dowlati, A
    Aisner, J
    Rigas, JR
    Stanislaus, M
    Leopold, LH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 645S - 645S
  • [44] Circulating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
    Heist, R. S.
    Motwani, M.
    Naumovski, L.
    Wu, J.
    Bach, B. A.
    Lu, X.
    Kelly, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).
    Papadimitrakopoulou, Vassiliki
    Wistuba, Ignacio Ivan
    Lee, J. Jack
    Tsao, Anne S.
    Kalhor, Neda
    Fossella, Frank V.
    Heymach, John
    Alden, Christine M.
    Gettinger, Scott N.
    Coombes, Kevin R.
    Saintigny, Pierre
    Tang, Ximing
    Duffield, Emily
    Boyer, Julie
    Davis, Suzanne E.
    Powis, Garth
    Mauro, David J.
    Rubin, Eric H.
    Hong, Waun Ki
    Herbst, Roy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] BATTLE-2 PROGRAM: A BIOMARKER-INTEGRATED TARGETED THERAPY STUDY IN PREVIOUSLY TREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Papadimitrakopoulou, Vassiliki
    Wistuba, Ignacio
    Lee, Jack J.
    Tsao, Anne
    Kalhor, Neda
    Fossella, Frank
    Heymach, John V.
    White, Ashley
    Gettinger, Scott N.
    Coombes, Kevin R.
    Saintigny, Pierre
    Tang, Ximing
    Duffield, Emily
    Boyer, Julie
    Wei, Caimiao
    Powis, Garth
    Mauro, David J.
    Rubiin, Eric H.
    Hong, Waun K.
    Herbst, Roy
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S367 - S367
  • [47] Phase I study of the antibody-drug conjugate BBV-321 in patients with non-small cell lung cancer and squamous head and neck cancer with overexpression of the epidermal growth factor receptor.
    Carneiro, Benedito A.
    Bestvina, Christine M.
    Shmueli, Einat Shacham
    Gan, Hui Kong
    Beck, Joseph Thaddeus
    Robinson, Randy
    Fischer, JuDee S.
    Wong, Amber
    Ansell, Peter J.
    Jin, Janet Yikai
    Naumovski, Louie
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
    Gazzah, Anas
    Ricordel, Charles
    Cousin, Sophie
    Cho, Byoung Chul
    Calvo, Emiliano
    Kim, Tae Min
    Helissey, Carole
    Kim, Jin-Soo
    Vieito, Maria
    Boni, Valentina
    Chadjaa, Mustapha
    Hospitel, Marie
    Yoruk, Semra
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] Xevinapant plus avelumab in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Phase 1b dose-expansion results and exploratory biomarker analyses
    Chu, Quincy
    Ciuleanu, Tudor
    Ramlau, Rodryg
    Renouf, Daniel
    Juergens, Rosalyn
    Kalinka, Ewa
    Sawrycki, Piotr
    Bramson, Jonathan
    Nelson, Brad
    Crabbe, Rafael
    Sahlender, Daniela A.
    Crompton, Philippa
    Rouits, Elisabeth
    Spaggiari, Dany
    Brichory, Franck
    Piggott, Luke
    Schenker, Mike
    Goss, Glenwood
    CANCER RESEARCH, 2023, 83 (08)
  • [50] Discovery and preclinical development of a highly potent NaPi2b-targeted antibody -drug conjugate (ADC) with significant activity in patient -derived non -small cell lung cancer (NSCLC) xenograft models
    Bodyak, Natalya
    Yurkovetskiy, Alex
    Yin, Mao
    Gumerov, Dmitry
    Bollu, Reddy
    Conlon, Patrick
    Gurijala, Venu R.
    McGillicuddy, Dennis
    Stevenson, Cheri
    Ter-Ovanesyan, Elena
    Park, Peter U.
    Poling, Laura
    Lee, Winnie
    Devit, Michael
    Xiao, Dongmei
    Qin, LiuLiang
    Lowinger, Timothy B.
    Bergstrom, Donald A.
    CANCER RESEARCH, 2016, 76
12345